IOVA - CIK 0001425205
IOVANCE BIOTHERAPEUTICS, INC. trades as IOVA and has a market capitalization of $1.69 B, making it the #2235 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $263.50M, up 60.6% from the prior year and net income of -$391.00M. This page tracks IOVANCE BIOTHERAPEUTICS, INC. through 1,005 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -37342.3% to -148.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-05-01 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| PRE 14A | - | 2026-04-17 |
The largest companies sharing IOVANCE BIOTHERAPEUTICS, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a market capitalization of $1.69 B as of 2026-06-10, ranking #2235 among US-listed companies.
IOVANCE BIOTHERAPEUTICS, INC. reported revenue of $263.50M for fiscal year 2025, an increase of 60.6% year over year.
In its latest fiscal year IOVANCE BIOTHERAPEUTICS, INC. reported a net loss of $391.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.